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Abstract
The characteristic features of Whipple’s disease include abdominal pain, diarrhoea, wasting, and arthralgias, with the causative agent, Tro-
pheryma whipplei, being detected mainly in intestinal biopsies. PCR technology has led to the identiﬁcation of T. whipplei in specimens
from various other locations, including the central nervous system and the heart. T. whipplei is now recognized as one of the causes of
culture-negative endocarditis, and endocarditis can be the only manifestation of the infection with T. whipplei. Although it is considered
a rare disease, the true incidence of endocarditis due to T. whipplei is not clearly established. With the increasing use of molecular
methods, it is likely that T. whipplei will be more frequently identiﬁed. Questions also remain about the genetic variability of T. whipplei
strains, optimal diagnostic procedures and therapeutic options. In the present study, we provide clinical data on four new patients with
documented endocarditis due to T. whipplei in the context of the available published literature. There was no clinical involvement of the
gastrointestinal tract. Genetic analysis of the T. whipplei strains with DNA isolated from the excised heart valves revealed little to no
genetic variability. In a selected case, we describe acridine orange staining for early detection of the disease, prompting early adaptation
of the antibiotic therapy. We provide long-term follow-up data on the patients. In our hands, an initial 2-week course of intravenous
antibiotics followed by cotrimoxazole for at least 1 year was a suitable treatment option for T. whipplei endocarditis.
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Introduction
In the original observation of a disease later named Whip-
ple’s disease after its ﬁrst describer George Hoyt Whipple, a
37-year-old male patient died of a chronic and consuming
disease dominated by gastrointestinal involvement, weight
loss and arthralgias [1]. Subsequently, Tropheryma whipplei
has been established as the causative agent of Whipple’s dis-
ease, and the rarity of the systemic disease has been docu-
mented in a historical review where only 15 post-mortem
cases were identiﬁed in approximately 900 000 reports [2].
Classically, the laboratory diagnosis of the disease has been
made by detection of Periodic acid-Schiff (PAS)-positive
inclusion bodies in the macrophages of the affected tissue.
However, PCR has become the most useful diagnostic test,
and the bacterium has been identiﬁed in tissues such as
intestine, joints, lungs, heart, central nervous system, eyes,
lymph nodes, liver, muscle and skin [3,4]. The signiﬁcance of
the detection of DNA from T. whipplei in a small proportion
of asymptomatic individuals in saliva, dental plaque, duode-
num and stool has remained unclear; it has been suggested
that, upon exposure to this soil microbe, host factors such
as a genetic predisposition may play a role in the develop-
ment of the disease [3].
Endocarditis due to T. whipplei can occur either in the set-
ting of systemic Whipple’s disease (referred to as Whipple’s
disease endocarditis) or as isolated endocarditis without clini-
cal or histological evidence for systemic Whipple’s disease
(referred to as isolated T. whipplei endocarditis). Reports of
isolated T. whipplei endocarditis have been published sub-
sequent to the early 1990s [5–7]. Current treatment recom-
mendations rely on in vitro data and on local experiences
[3,4], although a ﬁrst randomized controlled clinical trial has
been undertaken [3]. Follow-up data are scarce.
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The present study aimed to extend the clinical observa-
tions including long-term outcome by reporting four new
cases of isolated T. whipplei endocarditis in the context of
the available published literature. Because only a few cases of
well documented isolated T. whipplei endocarditis have been
published, we extended our review of the literature to all
cases with endocarditis due to T. whipplei. We also report
on the genetic variability of the four strains isolated at our
institution and on a rapid diagnostic approach for early suspi-
cion of the disease.
Materials and methods
Patient selection and review of the literature
A systematic review of all cases of T. whipplei infections at
our institution, a university hospital with specialized microbi-
ological laboratories and serving an estimated population of
1.2 million, between January 2000 and December 2008 iden-
tiﬁed a total of 14 positive specimens in 12 patients. Four of
these patients had an isolated infection of the heart valve
and are reported here. Informed consent was obtained from
all four patients.
A thorough search using the PubMed database (http://
www.ncbi.nlm.nih.gov/pubmed) and the keywords ‘Trophe-
ryma’, ‘Whipple’ and ‘endocarditis’ and cross-referencing
from the resulting reports were used for the review of the
published literature up to June 2009.
PCR method
Total genomic DNA from each sample was extracted using
the HighPure kit (Roche Diagnostics, Basel, Switzerland).
Three target regions were ampliﬁed following published pro-
cedures: hsp65 using primer pair whipp-frw1/rev [8], and
two highly variable genomic sequences using primer pairs
HVGS1f/r and HVGS4f/r [9]. PCR products were analysed
on a 2% agarose gel, puriﬁed using HighPure PCR puriﬁca-
tion kit (Roche Diagnostics) and sequenced in both direc-
tions using the same primers as for ampliﬁcation. Sequence
homologies were determined using BLAST (http://www.ncbi.
nlm.nih.gov/blast/Blast.cgi).
Acridine orange stain
The excised heart valve was crushed against a glass slide
(squash preparation), heat-ﬁxed in accordance with standard
procedures, incubated for 2 min with acridine orange (Difco,
Chemie Brunschwig AG, Basel, Switzerland), washed and
examined under a ﬂuorescence microscope.
Results
Incidence
Between January 2000 and December 2008, T. whipplei was
detected by PCR in duodenal biopsies from eight patients
(estimated overall incidence for Whipple’s disease of 1.1 per
1 000 000 individuals per year), and exclusively in excised
heart valve of another four patients, all between 2004 and
2007.
In the literature, estimates of the overall incidence of
Whipple’s disease are less than 1 per 1 000 000 population
per year [3]. However, information about the frequency of
isolated T. whipplei endocarditis is scarce. PCR analyses of
cardiac valves in the presence of a clinical diagnosis of infec-
tious endocarditis has shown positivity for T. whipplei from 0
of 390 samples up to four of 21 samples (Table 1).
TABLE 1. Reported PCR analyses for Tropheryma whipplei of heart valves in patients with clinical diagnosis of infectious endo-
carditis (IE)
Time span
[reference] Country Type of study
Patient
characteristics
Number of
samples
with positive
PCR
Total number
of samples
analysed Type of PCR
1995–2007 [24] France Retrospective analysis Suspicion of Whipple’s disease,
or culture-negative IE
6a 200b T. whipplei-speciﬁc PCR
18 months [51] Germany Cross-sectional observational study Suspected IE 0 52c Broad-range PCRd
28 months [52] England Prospective controlled study Possible or deﬁnite IE 0 37 Broad-range PCRd
35 months [25] Denmark Prospective controlled study Deﬁnite IE 2 57 Broad-range PCRd
3 years [26] Czech Republic Retrospective case–control study Culture-negative IE 1 17e Broad-range PCRd
34 months [27] Spain Retrospective case–control study Deﬁnite IE 1f 35 Broad-range PCRd
20 months [5] Switzerland Prospective observational study Suspicion of Whipple’s disease,
or culture-negative IE
4 21 Broad-range PCRd and
T. whipplei-speciﬁc PCR
39 months [28] Switzerland Retrospective controlled study Possible or deﬁnite IE 1f 35 Broad-range PCRd
aThree patients had culture-negative IE, and three Whipple’s disease.
bIncludes samples from various tissues, no details given.
cFifty-two samples from 51 patients.
dPCR analysis by panbacterial broad-range 16S rRNA PCR.
eSeventeen samples from 15 patients.
fPositivity was conﬁrmed by performing T. whipplei-speciﬁc PCR.
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Patients
All four patients with T. whipplei endocarditis from our insti-
tution were male; their mean age was 69.5 years (range 54–
78 years). Clinical and laboratory features are summarized in
Table 2 (for detailed information, see Supporting Informa-
tion, Data S1).
Review of the literature
The most comprehensive review of endocarditis due to
T. whipplei up to 2001 lists 58 conﬁrmed cases [7], and men-
tions four more cases [10–12] and two possible ones
[13,14]. The review summarizes the characteristics of 35 of
these 64 patients. In another report, heart valve involvement
was noted in ﬁve out of ﬁve patients at autopsy without
prior diagnosis of endocarditis [15]. Double-reporting is not
uncommon, and this potentially overestimates the incidence
[16–20]. Finally, recently published molecular analyses some-
times include samples from previously published cases [9,21–
23]. Together, these reviews, reports and analyses total at
least 70 cases of endocarditis due to T. whipplei, originating
from Northern America, Germany, France, Switzerland, The
Netherlands and South Africa.
Our review of the literature encompasses the period up
to June 2009 and adds another 27 cases resulting in at least
97 cases of endocarditis due to T. whipplei; the additional
reports include patients from the UK, the Czech Republic,
Spain, Brazil, Denmark, the Antilles and Tunisia [6,24–43].
Patients 1, 3, 6, 11, 16 and 26 had no symptoms other than
those attributable to endocarditis and, in four of them
(patients 1, 3, 16 and 26), analyses of the intestinal biopsies
were negative, leading to the diagnosis of isolated T. whipplei
endocarditis (patient characteristics shown in Tables 3 and
4; for a detailed analysis, see Supporting Information,
Data S2).
Genotyping
From our four patients, DNA products were readily ampli-
ﬁed using primer pairs HVGS1, HVGS4 and whipp (Fig. 1).
Sequencing showed identical HGVS4 and whipp sequences in
all four patients, and a difference of one nucleotide in
TABLE 2. Patient characteristics
Patient 1 Patient 2 Patient 3 Patient 4
Age (years) 54 78 70 76
Sex Male Male Male Male
Occupation Mechanical plant engineer Farmer Sanitary systems store manager Builder
Presenting symptom Branch retinal artery occlusion Biventricular heart insufﬁciency Biventricular heart insufﬁciency Middle cerebral artery
occlusion
Other symptoms
Arthropathy Yes No No No
Diarrhoea No No No No
Weight loss No No No (low alb) Yes
Night sweats No No No Yes
Fatigue No No No Yes
Fever No No No No
Comorbidities Osteomyelitis, chronic
hepatitis C, tooth pain
Coronary heart disease,
renal failure
Pachypleuresy, chronic
obstructive lung disease,
alcoholism, peripheral
arterial disease, bilateral hip
prostheses
Prostate cancer, arterial
hypertension, renal failure,
heart insufﬁciency, previous
strokes
Vegetation (by TEE) Aortic valve Aortic valve Mitral valve Mitral valve
Laboratory values
Haemoglobin, g/L 124 112 (normochromic,
normocytic)
118 (normochromic,
normocytic)
109 (normochro-mic,
normocytic)
Leukocytes, ·109/L 6.7 7.9 7.1 8.1
Platelets, ·109/L 205 170 161 190
CRP mg/L 24 33 15 47
Investigations
Blood cultures Negative Negative Negative Negative
Valve biopsy
PCR Positive Positive Positive Positive
Histology Chronic active granulating
ﬁbrino-purulent inﬂammation
Not done Granulocytic inﬂammation,
sclerohyalinosis, giant cell
reaction with vascularization,
mucoid degeneration of
connective tissue
Purulent-granulating, ﬁbrinoid
exsudative inﬂammation,
myxoid leaﬂet degeneration
PAS Positive intra- and extracellular Not done Positive in macrophages Negative
Duodenal biopsy Not done Not done Not done Not done
Other Stool PCR: negative – – –
Therapy after diagnosis Cef 1 · 2 g/d and G for
4 w; C 1 y
Cef 1 · 2 g/d for 2 w; C 1 y Cef 2 · 2 g/d for 2 w; C 1 y Cef 2 · 2 g/d for 2 w; C 1 y
Outcome Well after 4.5 y Well after 4.5 y Well after 2 y Well after 2 y
TEE, transoesophageal echocardiography; CRP, C-reactive protein; PAS, Periodic acid-Schiff; d, day; w, week; y, year; alb, albumin; Cef, ceftriaxone; C, cotrimoxazole (800 mg
sulphamethoxazole and 160 mg trimethoprim twice a day).
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TABLE 3. Characteristics of patients with endocarditis due to Tropheryma whipplei: signs and symptomsa
Case
[reference]
Country
of origin Age Sex IS
Presenting
symptom Fever Other symptoms
Comorbidities,
medical history Cardiac murmur
1 [29] UK 58 M No Heart failure No No Alcoholic
cardiomyopathy
–
2 [30] UK 38 M – Heart failure – – Bicuspid aortic valve Aortic, mitral
regurgitant
3 [31] USA 78 M – Heart failure – No Angina pectoris,
congestive heart
failure
3/6 systolic
4 [32] USA 43 M No Unilateral hearing
loss, personality
changes, cough
38.1C Anorexia, weight loss,
hypercalcaemia, joint
stiffness
History of
thromboses and
stroke, recurrent left
eye infection,
chronic cough,
pruritus
2/6 holosystolic at the
apex with radiation
to the axilla
5 [33] Canada 65 M No Heart failure No Malaise, night sweats,
weight loss, fatigue
Bicuspid aortic valve,
history of heart
failure and transient
ischaemic attack
–
6 [33] Canada 51 M No Ischaemia right arm,
cerebral, renal and
splenic infarcts
No No Bicuspid aortic valve,
gout, hypertension,
cervical spine fusion
–
7 [34] Germany 80 F No Heart failure No Myalgia for 2 months Valve surgery
22 months
previously
–
8 [35] Germany 69 M No Heart failure No Dyspnoea, weight loss Diabetes mellitus type
2, hypertension,
myocardial
infarction, history
of stroke
–
9 [36] Germany 74 M No Heart failure – Weight loss, arthralgia Angina pectoris,
history of stroke
valve surgery
20 months
previously
Yes
10 [37] Czech
Republic
33 M No Stroke, acute left
upper arm ischaemia
38.5C Arthralgia Bicuspid aortic valve Yes
11 [26] Czech
Republic
68 M No Valve dysfunction,
persistent infection
– No Coronary heart
disease, history of
spinal and hand
trauma
–
12 [24] Franceb 45 M – ‘multisystemic’ – – – –
13 [24] Franceb 50 M – ‘endocarditis’ – – – –
14 [6] Francec 51 M No Fever, heart failure 38.2C Arthralgia, splenic
infarct
Seronegative
polyarthritis
2/6 systolo-diastolic
15 [28] Switzerland – – – Heart failure – Arthralgia Seronegative
spondylarthritis
–
16 [53] Spain 51 M No Heart failure 37.2C No No Grade II/IV
systolo-diastolic
17 [38] Brazil 59 M No Chronic epigastric
colic pain
39.0C Anorexia, weight loss,
arthralgia
Psoriasis, psoriatic
spondylitis
Systolic
18 [38] Brazil 41 F No Rotary dizziness,
hearing loss
No Arthralgia, anorexia,
diarrhoea, weight
loss
No Systolic
19 [38] Brazil 28 M – Uveitis with retinal
haemorrhage
Yes Diarrhoea, weight
loss, malaise
– Protomesosystolic on
the left sternal
margin
20 [25] Denmark 51 M No Heart failure No Fatigue, abdominal
pain
History of lower back
pain, fever,
thrombosis
Systole-diastolic
21 [25] Denmark 67 M Yes Heart failure No Arthralgia History of polymyalgia
and tendinitis
No
22 [39] France 61 M Yes Fever, wasting Yes – Suspicion of
sarcoidosis
–
23 [40] France 64 M No – No Arthralgia, diarrhoea,
weight loss, wasting
– –
24 [41] France
(Antilles)
58 M No Fever, wasting Yes Arthralgia, diarrhoea,
weight loss
Hypertension 2–3/6 systolo-diastolic
25 [41] Tunisia 59 F No Arthralgia Yes Wasting, weight loss Arthralgia 2–3/6 systolo-diastolic
26 [42] France 62 M No Recurrent strokes,
left lower limb
ischaemia
Yes No Hypertension No
27 [43] Germany 54 F Yes Wasting, heart failure Yes Arthralgia Dermatomyositis –
aNot mentioned are patients cited in previous reviews and referenced in the text [4,15].
bStudy also contains ﬁve patients from ref [6].
cStudy also contains two patients from ref [21], and two patients from ref [54] (1999). M, male; F, female; IS, immunosuppression;–, not reported/no details given.
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HVGS1 for patient 3 (amplicon nucleotide 87 T/C). In this
limited number of patients, there was very little genetic vari-
ation. All but one sequence showed 100% identity with
TW08/27; only HVGS1 in patient 3 was identical to T. whipp-
lei genotype 6. All sequences belong to the same published
phylogenetic cluster [9].
Acridine orange stain
Acridine orange is a ﬂuorescent stain that interacts by inter-
calation with nucleic acids. Bacterial concentrations as low as
1 · 104/mL can be detected. In patient 1, numerous intra-
and extracellular microorganisms were shown by acridine
orange, but not Gram’s stain, of the native valve squash
preparation (Fig. 2). No microorganisms were seen in the
other patients.
Discussion
The published data reviewed here suggest that endocarditis
due to T. whipplei occurs not infrequently without any of the
classical features of Whipple’s disease. At least six out of 27
patients in the present series did not have any symptoms
other than those attributable to endocarditis
[26,27,29,31,33,42], and our four patients clinically had no
gastrointestinal involvement, ﬁtting the diagnosis of isolated
T. whipplei endocarditis. In patient 4 of our series a systemic
involvement could not be excluded; however, weight loss
and night sweats were considered to be manifestations of his
underlying cancer. Thus, T. whipplei must be part of the diag-
nostic work-up of culture-negative endocarditis, even in the
absence of other symptoms pointing to the diagnosis of
Whipple’s disease.
Including the four patients we report here and those in
the reviewed literature, only 101 patients with endocarditis
due to T. whipplei have been reported worldwide. The
observed differences in the reported detection rate of
T. whipplei in cardiac valves in the case of clinical diagnosis
of infectious endocarditis (Table 1) might be as a result of
geographic differences, analytical speciﬁcs including choice of
primers, and empirical antibiotic treatment before valve
replacement. However, under-reporting and missed diagnosis
are likely and emphasize the need for the systematic registra-
tion of cases. The cumulative data show that T. whipplei is
encountered worldwide, in cold as well as in warm climatic
regions.
The four patients reported here provide only limited
epidemiological data. The disease is encountered mainly in
men aged over 50 years. The mean ages recorded were: in
our four patients, 69.5 years; in the updated review, 56 years;T
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and in the previous reviews, 57 and 49 years, respectively
[6,7]. All four of our patients undertook outdoor activities,
and three out of four were active in the building and/or
plumbing industry. The most common accompanying symp-
toms are fatigue and weight loss (one of our patients, 48% in
the updated review) and arthralgia (one of our patients, 48%
in the literature update). Fever is less common (none of our
patients, 41% in the literature update) and, when present, is
often low-grade. The analysis shows a predisposition for the
valves of the left heart. Because the left outﬂow tract endures
high stress, its endothelial layers may be more easily subject
to damage, thus predisposing to the development of endocar-
ditis [44]. Interestingly, none of our patients was found to
have a predisposing cardiac condition, whereas four patients
in the updated review had a bicuspid aortic valve, and two an
aortic bioprosthesis. As previously noted, this suggests that
endocarditis due to T. whipplei can develop without preexist-
ing cardiac abnormalities [7]. Valve vegetations were seen in
all of our patients but have been inconsistently reported in
the literature. Only 52% of the patients in our updated
review had vegetations. Thus, the absence of vegetations
does not rule out the possibility of endocarditis due to
T. whipplei, and some patients with the disease do not fulﬁl
the modiﬁed Duke criteria for a deﬁnite diagnosis of infective
endocarditis [45]. Laboratory ﬁndings typically include normal
leucocyte count, moderately elevated C-reactive protein
level, elevated erythrocyte sedimentation rate, anaemia, and
normal serum albumin, which are all features that reﬂect the
chronic nature of the disease with at most a mild inﬂamma-
tory response to T. whipplei. Accordingly, anaemia is mostly
normochromic and normocytic; if reduced red cell indices
are found, this may indicate involvement of the gastrointesti-
nal tract, with malabsorption. Taken together, the most help-
ful symptoms and laboratory signs suggesting endocarditis
due to T. whipplei are affected valves on the left side of the
heart in the presence of moderate wasting and/or arthralgia,
without signiﬁcant inﬂammatory signs.
Genotype analyses showed close homology among the
four examined strains and with reference strains. The data
suggest a limited genetic variability in T. whipplei strains caus-
ing endocarditis, at least in our geographic region. This is in
contrast to published data on ﬁve patients with endocarditis
and heterogeneous genotypes [9]; however, in that report,
patients originated from three different countries and only
one patient was from Switzerland. Finally, our data conﬁrm
that endocarditis due to T. whipplei is not associated with a
single strain sequence, and that host factors may be involved.
Available data show no clear association between the
bacterial genotype and the clinical symptoms in the host [9].
In most of the published cases, the diagnosis of endocardi-
tis due to T. whipplei was made from the excised valve tissue.
Histology is nonspeciﬁc and shows chronic inﬂammatory
changes (as well as, in one case of our series, calciﬁcation),
FIG. 2. Microscopic examination of the excised valve (squash prepa-
ration). Numerous extracellular ﬁne rod-like organisms are visible in
an acridine orange stain (arrows; Zeiss Axioplan 2 imaging, ﬁlter set
09, · 1000; Carl Zeiss, Oberkochen, Germany).
M
neg co
HVGS1 HVGS4 whipp
246 bp
199 bp
504 bp
P1 P2 P3 P3 P4P1 P2 P3 P3 P4P1 P2 P3 P3 P4 M
FIG. 1. Tropheryma whipplei DNA ampli-
cons separated using a 2% agarose gel.
Lanes 2–5, negative primer controls
without DNA (neg co). Following lanes,
DNA from patients 1–4 (P1, P2, P3, P4),
with two different heart valve tissue
probes of patient 3, ampliﬁed with pri-
mer pairs HVGS1 (lanes 6–10, 246 bp),
HVGS4 (lanes 11––15, 199 bp), whipp
(lanes 17–21, 504 bp). M, marker lanes.
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which have also been observed in previous cases [6]. In our
hands, PAS analysis gave variable results. In two cases, organ-
isms were shown in macrophages, and in one case also
extracellularly. In one case, PAS analysis was negative and
only PCR identiﬁed the causative organism. Thus, analysis by
PCR may be more sensitive than PAS staining, and PCR anal-
ysis using at least universal bacterial primers should be used
on excised valves in cases of culture-negative infective endo-
carditis [23,25,30].
A surprising observation was the detection of the organ-
ism both intra- and extracellularly in patient 1. Using an acri-
dine orange stain, the bacteria were directly visualized in the
native valve. This led to an early suspicion of T. whipplei
endocarditis and the start of appropriate antibiotic therapy.
The acridine orange stain has previously been used on
T. whipplei cultures [46], but not on native valves. It is more
sensitive than the PAS stain, and far easier to handle than a
previously favoured silver stain [5]. In our case, large num-
bers of microorganisms were visible extracellularly, as has
been reported previously [34,47]. Thus, acridine orange
stain on a squash preparation of the valve may be useful
early in the diagnostic work-up of culture-negative infective
endocarditis.
In cases where endocarditis is present in the context of
suspected systemic Whipple’s disease, aetiological diagnosis
should be attempted with noncardiac tissues because endo-
carditis may resolve with antibiotic therapy of the systemic
disease. In eight reported cases with systemic Whipple’s dis-
ease, cardiac involvement compatible with infective endocar-
ditis according to the Duke criteria was suspected based on
echographic ﬁndings (vegetations in ﬁve cases and valvular
insufﬁciencies in three) [45,48]. Demonstration of T. whipplei
in tissues other than the cardiac valves allowed a deﬁnitive
diagnosis (Table 4) [38–41,43]. In those patients, long-term
antibiotic treatment led to resolution of the valve vegetation
in two patients, whereas, in the other cases, cardiac function
was stabilized; there was no need for cardiac surgery.
Therapy after diagnosis in all of our four cases was intra-
venous ceftriaxone for 2 weeks, followed by 1 year of
cotrimoxazole, as reported previously [49]. In all cases, the
outcome after a follow-up of 2–4.5 years was good, with
resolution of all symptoms. It is notable that accompanying
arthropathy resolved within weeks to months after the initia-
tion of the antibiotic therapy. The rapid resolution of accom-
panying symptoms has been previously noted [38,40,41] and
may be used as an indicator of successful therapy of the
cardiac affection. In our hands, cotrimoxazole for 1 year was
a suitable therapy for endocarditis due to T. whipplei, and,
because the patients remain asymptomatic, no speciﬁc
follow-up schedule has been established. However, it is
important to collect more long-term data on cases of endo-
carditis due to T. whipplei because, in at least three published
cases, resistance to cotrimoxazole has been reported [50].
In those cases, a combination treatment, with doxycycline
200 mg/day and hydroxychloroquine 200 mg three times a
day, is proposed [50].
In conclusion, the results obtained in the present study
suggest that the incidence of endocarditis due to T. whipplei
is higher than previously reported. T. whipplei must be con-
sidered as a possible causative organism in any case of
culture-negative endocarditis, especially as the disease is
chronically destructive and ultimately fatal if not effectively
treated with adequate antibiotic therapy. Collection of more
information on endocarditis due to T. whipplei by the inclu-
sion of new cases in registries may help resolve open ques-
tions about the disease, its origin, risk factors, therapy and
preventive measures.
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